Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 12Lung Neoplasms 3Neoplasms 2Thoracic Neoplasms 1Squamous Non-small Cell Lung Cancer 1Squamous Non Small Cell Lung Cancer 1Solid Tumors 1Solid Tumor, Adult 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Non-small Cell Lung Cancer Metastatic 1Neoplasm Metastasis 1Lung Diseases 1Colorectal Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma 1Breast Neoplasms 1

Interventions

Paclitaxel 3Carboplatin 3tremelimumab 1pembrolizumab 1necitumumab 1envafolimab 1durvalumab 1anlotinib 1Nivolumab 1Gemcitabine 1Endostatins 1Drug Therapy 1Cisplatin 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Squamous Non-small Cell Lung Cancer × necitumumab × Clear all
NCT01763788 2019-10-25

A Study of Necitumumab in the First-Line Treatment of Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)

Eli Lilly and Company

Phase 1/2 Completed
192 enrolled 24 charts
Thoracic

Squamous Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡